
Quarterly report 2025-Q2
added 08-06-2025
OrthoPediatrics Corp. Net Debt 2011-2026 | KIDS
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt OrthoPediatrics Corp.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 31.3 M | -20.8 M | -9.56 M | -7.96 M | -29 M | -44.6 M | -39.4 M | -17.1 M | 15.9 M | 9.26 M | 6.66 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 31.3 M | -44.6 M | -9.57 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Medical devices industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Acutus Medical
AFIB
|
14.2 M | - | -26.83 % | $ 2.62 M | ||
|
Alphatec Holdings
ATEC
|
347 M | $ 13.94 | -0.71 % | $ 2.09 B | ||
|
Allied Healthcare Products
AHPI
|
-3.31 M | - | 3.58 % | $ 2.21 M | ||
|
ClearPoint Neuro
CLPT
|
-16.5 M | $ 14.09 | -7.06 % | $ 381 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
38.7 M | - | - | $ 1.77 B | ||
|
Apollo Endosurgery
APEN
|
-22.5 M | - | - | $ 475 M | ||
|
Avinger
AVGR
|
-16.3 M | - | -20.74 % | $ 369 K | ||
|
Obalon Therapeutics, Inc.
OBLN
|
6.46 M | - | -5.86 % | $ 30.6 M | ||
|
AxoGen
AXGN
|
15.2 M | $ 31.87 | 2.07 % | $ 1.47 B | ||
|
Cognyte Software Ltd.
CGNT
|
-47.4 M | $ 7.0 | 5.74 % | $ 503 M | ||
|
EDAP TMS S.A.
EDAP
|
-22.8 M | $ 4.38 | -4.58 % | $ 163 M | ||
|
Axonics Modulation Technologies
AXNX
|
-230 M | - | - | $ 3.31 B | ||
|
Electromed
ELMD
|
-10.5 M | $ 24.18 | 1.09 % | $ 204 M | ||
|
Aziyo Biologics
AZYO
|
1.36 M | - | 1.37 % | $ 20.5 M | ||
|
Apyx Medical Corporation
APYX
|
-10.1 M | $ 3.49 | 2.05 % | $ 121 M | ||
|
Conformis
CFMS
|
-26.2 M | - | - | $ 16.4 M | ||
|
Bio-Rad Laboratories
BIO
|
754 M | $ 275.33 | 2.19 % | $ 7.77 B | ||
|
BIOLASE
BIOL
|
6.1 M | - | -13.19 % | $ 166 K | ||
|
Bruker Corporation
BRKR
|
1.91 B | $ 40.88 | 2.48 % | $ 6.09 K | ||
|
BioSig Technologies
BSGM
|
252 K | - | 37.08 % | $ 85.7 M | ||
|
Boston Scientific Corporation
BSX
|
9.26 B | $ 75.65 | 2.97 % | $ 112 B | ||
|
InMode Ltd.
INMD
|
-34.8 M | $ 14.0 | 0.29 % | $ 905 M | ||
|
IRIDEX Corporation
IRIX
|
-4.29 M | $ 1.47 | -2.0 % | $ 23.7 M | ||
|
IRadimed Corporation
IRMD
|
-52.1 M | $ 102.4 | 1.89 % | $ 1.3 B | ||
|
CryoLife, Inc.
CRY
|
230 M | - | -4.14 % | $ 702 M | ||
|
CONMED Corporation
CNMD
|
802 M | $ 45.89 | -0.18 % | $ 1.42 B | ||
|
Soliton, Inc.
SOLY
|
-31.6 M | - | -1.42 % | $ 435 M | ||
|
Cardiovascular Systems
CSII
|
-64.6 M | - | 0.15 % | $ 844 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
-9.02 K | - | -1.98 % | $ 98.3 M | ||
|
LivaNova PLC
LIVN
|
-282 M | $ 71.26 | 1.38 % | $ 3.89 B | ||
|
Itamar Medical Ltd.
ITMR
|
-2.3 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
5.72 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
-4.95 M | - | - | $ 111 M | ||
|
Cutera
CUTR
|
-140 M | - | -10.19 % | $ 1.99 M | ||
|
Medtronic PLC
MDT
|
23.6 B | $ 97.22 | 0.58 % | $ 125 B | ||
|
Delcath Systems
DCTH
|
-2.46 M | $ 9.11 | -10.77 % | $ 260 M | ||
|
Intersect ENT, Inc.
XENT
|
50.8 M | - | - | $ 955 M | ||
|
Dynatronics Corporation
DYNT
|
1.8 M | - | 14.99 % | $ 929 K | ||
|
Eargo
EAR
|
-97.8 M | - | - | $ 10.2 M | ||
|
Second Sight Medical Products
EYES
|
961 K | - | -0.97 % | $ 54.4 M | ||
|
Establishment Labs Holdings
ESTA
|
131 M | $ 77.41 | -1.12 % | $ 2.18 B | ||
|
Insulet Corporation
PODD
|
468 M | $ 251.74 | 1.46 % | $ 17.7 B | ||
|
Quanterix Corporation
QTRX
|
-133 M | $ 6.7 | 6.52 % | $ 252 M | ||
|
GBS
GBS
|
-4.38 M | - | -0.57 % | $ 7.12 M | ||
|
FONAR Corporation
FONR
|
-42.8 M | $ 18.53 | -0.3 % | $ 121 M | ||
|
Sintx Technologies
SINT
|
859 K | $ 2.89 | -1.87 % | $ 10.8 M | ||
|
MiMedx Group
MDXG
|
-148 M | $ 4.97 | -5.78 % | $ 735 M |